retatrutide active ingredient Retatrutide, an experimental weight-loss drug,
Description
The Phase 2 trial tested doses from 0.5mg to 12mg, with 2mg as the standard starting dose for titration
Patients experiencing significant gastrointestinal side effects from semaglutideparticularly nausea, vomiting, or diarrheashould avoid alcohol until these symptoms resolve

To note, the study population lacked fibrosis, so claims about retatrutides potential to reverse fibrosis should be considered preliminary at best

The decrease in SBP can be attributed to the natriuresis induced by SGLT2is [59]

Testing reveals genetic variants in GLP1R, GIPR, and FTO genes that predict how your body processes semaglutide and manages body weight, helping your provider personalize your dose and predict menstrual stability
